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Victoria’s continued progress in controlling the HIV/AIDS epidemic is under threat.
For the second year in a row HIV diagnoses have increased.  In 2001 218 people were
diagnosed with HIV; a 56 per cent increase on the 1999 figure of 139 cases.  Here we
present an analysis of Victorian HIV surveillance data for the year 2001.
SUMMARY OF TRENDS IN HIV IN
VICTORIA 
The increase in new diagnoses first
observed in Victoria in 2000 has
continued in 2001.  The major proportion
of this increase is attributable to a rise in
HIV diagnoses among men who have sex
with men.  HIV diagnoses in this group
have risen from 80 in 1999 to 150 in 2001;
an 88 per cent increase.  In 2001 12 cases
of HIV were diagnosed in heterosexual
women.  This is a 77 per cent increase on
the seven cases diagnosed in 2000.
Eleven new cases of HIV were diagnosed
in people whose main exposure was
injecting drug use (IDU) in 2001, the
same number as in 2000.  However, these
numbers are on average at least double
those recorded throughout most of the
1990s.  This increase is mainly due to a
sharp rise in the number of diagnoses
among persons from Indochina who
inject drugs. The annual number of
newly acquired infections during 2001
also rose to 72, representing a third of
total diagnoses (Table 1).
HIV/AIDS IN VICTORIA
From 1983 to the end of 2001, there were
a cumulative total of 4629 HIV diagnoses
in Victoria.  This represents about 21 per
cent of Australia’s total.  Males account
for 4329 diagnoses (94 per cent) and
females account for 257 (5 per cent).  The
annual number of HIV diagnoses in
Victoria peaked in 1985 with 528
diagnoses (Figure 1).
Table 1: Summary of Trends in HIV in Victoria, 1999 to 2001
1999 2000 2001 Change 
1999–2001
N Per cent N Per cent N Per cent Per cent
Total cases 139 100 197 100 218 100 +56
Males 127 91.4 176 89.3 193 93.5 +52
Females 12 8.6 20 10.2 23 5.6 +91
MSM 80 57.5 127 64.5 150 78 +88
IDU 5 3.6 11 5.6 11 5.0 +122
New infections 42 30 64 32 72 33 +71
The cumulative total of AIDS diagnoses in Victoria until
the end of 2001 was 1942.  The annual number of AIDS
diagnoses in Victoria peaked at 203 in 1994 and has
since fallen rapidly to 44 in 2001.
EPIDEMIOLOGY OF HIV IN VICTORIA DURING
2001
In 2001, 218 cases of HIV were diagnosed in Victoria.
This is the highest annual number of notifications since
1994.  Of these 193 (89 per cent) were males, 23 (11 per
cent) were females and there were two transgender
individuals.  The median age at diagnosis was 32 years
for males (range: 20 to 73 years) and 30 years for
females (range: 0 to 54 years).  Although the majority
(73 per cent) of diagnoses were among individuals aged
between 25 and 44 years, seven (3 per cent) were aged
under 20 years and three (1.5 per cent) were aged over
60 years. 
Over three quarters of individuals diagnosed with HIV
lived in metropolitan Melbourne, with the largest
number residing in the Southern Metropolitan Region
(79 people or 36 per cent) and the second largest number
in the Northern Metropolitan Region (53 people, or 
24 per cent). Seventeen (8 per cent) individuals were
resident in non-metropolitan Melbourne, while post-
code information was unavailable for 15 (seven per cent)
cases.  The regional distribution of cases is similar to that
observed in 2000 however, in some regions, the crude
population rate of HIV has increased substantially
(Table 2).
RISK FACTORS IN MALES IN 2001
There were 193 males diagnosed with HIV infection.
Male-to-male sexual contact (homosexual and bisexual)
accounted for 150 (78 per cent) diagnoses. There were
15 (8 per cent) diagnoses notified reporting hetero-
sexual contact, compared with 14 (8 per cent) in 2000
and 16 (13 per cent) in 1999.  
There was a decrease in the number of males diagnosed
with HIV who originated from a high prevalence
country.*  Five (3 per cent) such males were diagnosed,
compared with 11 (6 per cent) in 2000 and seven (6 per
cent) in 1999.
Six males (3 per cent) reported both injecting drug use
and male-to-male sexual contact.  Nine (5 per cent)
males reported injecting drug use alone.  No exposure
information was available for an additional five (3 per
cent) infections notified.
Most (58 per cent) males were tested as a result of
perceived high-risk behaviour—that is, sexual practices
and/or injecting drug use.  Three-quarters of all males
were symptomatic at the time of testing; 24 percent
were tested as a result of HIV symptoms including
symptoms of AIDS and nine per cent presented with an
acute seroconversion illness.  Seven males (4 per cent)
were also diagnosed with gonorrhoea at the time that
they were tested for HIV.
Males reporting male-to-male sexual contact were more
likely than males reporting heterosexual contact to
report that they had acquired their infection in Australia
(84 per cent versus 40 percent). Males reporting
heterosexual contact were more likely than those
reporting male-to-male sexual contact to report that they
had acquired their infection overseas (53 per cent versus
8 per cent).
There was little variation in the proportion of source
partners identified as casual or anonymous between
males reporting male-to-male sexual contact  (63 per
cent) and those reporting heterosexual contact (60 per
cent).  Regular sexual partners were identified as the
most likely source of HIV infection by 25 per cent of
those reporting male-to-male sexual contact and 27 per
cent of those reporting heterosexual contact.
RISK FACTORS IN FEMALES IN 2001
There were 23 females diagnosed with HIV infection.
This increase was largely attributable to a greater
number of notifications from women reporting
heterosexual contact.  Heterosexual contact accounted
for 12 diagnoses (52 per cent of the total) and
originating from a high prevalence country accounted
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Figure 1: HIV and AIDS Notifications, 1983–2001, Victoria
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Table 2: HIV Diagnoses and Notification Rate per 100,000 Population 
by DHS Region, 1999–2001, Victoria*
1999 2000 2001
Number Rate Number Rate Number Rate
Barwon South 2 0.6 5 1.5 6 1.8
Western
Eastern 13 1.3 27 2.8 24 2.5
Metropolitan
Gippsland 4 1.7 5 2.1 0 0
Grampians 5 2.5 8 3.9 0 0
Hume 2 0.8 4 1.6 4 1.6
Loddon Mallee 2 0.7 2 0.7 7 2.4
Northern 28 3.7 45 5.9 53 6.9
Metropolitan
Southern 41 3.7 55 4.9 79 7.1
Metropolitan
Western 21 3.4 29 4.8 30 4.9
Metropolitan
Victoria total# 139 2.9 197 4.1 218 4.6
*Denominator ABS Estimated Resident Population (2000)
#Includes cases for whom regional details were unavailable
* High prevalence countries include those in sub-Saharan Africa, the
Carribean and specified countries in South-East Asia (Cambodia,
Myanmar and Thailand), where HIV is transmitted predominantly by
heterosexual contact.
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for seven (30 percent). Two females (9 per cent) reported
injecting drug use.  The remaining two cases in females
were attributed to vertical transmission.
Twenty-six per cent of females were tested because of
high-risk behaviour, with another five (22 per cent)
tested because of HIV symptoms.  Three females (13 per
cent) were tested during antenatal screening.
Eleven (48 per cent) females reported that they had
acquired their infection overseas and nine (39 per cent)
in Australia.  The place of acquisition of HIV infection
was unknown for the remaining three (13 percent)
females. Women were much more likely than men to
identify their regular partner as the source of their HIV
infection; 61 per cent as opposed to 24 per cent.
HIV AMONG PERSONS WHO INJECT DRUGS IN
2001
There were 15 males diagnosed with HIV who had a
history of injecting drug use.  Of these, six men reported
a history of male-to-male sexual contact; a decrease
compared with the seven men in this category notified
during 2000 and the 12 notified in 1999.  Nine males,
five of whom were from Indochina, reported injecting
drug use alone; a slight decrease on the 10 notified in
2000 but still substantially higher than any other year
since 1990 when 13 such males were notified.  
Those with a history of injecting drug use without
male-to-male sexual contact tend to be younger than all
others diagnosed with HIV (an average of 28 years
compared with 33 years).
NEWLY ACQUIRED INFECTIONS DIAGNOSED
DURING 2001
Those with newly acquired or incident HIV infection
provide a picture of who is presently being affected by
the HIV epidemic.  Such individuals are identified on
the basis of a previous negative HIV test and/or a
seroconversion illness within the 12 months preceding
HIV diagnosis. Seventy-two newly acquired HIV
infections were notified; males accounted for 92 per cent
and male-to-male sexual contact was reported by 92 per
cent of these.  Gay identified males are, however, more
likely to be diagnosed with incident infection because
many serially test for HIV and attend a gay or specialist
medical practice in which the doctors are familiar with
the clinical presentation of a seroconversion illness.
Data about incident infection must be treated with
caution because many of the reports by patients of
either seroconversion illnesses or previous negative
tests are unable to be verified.  If incident infection were
to be defined only on the basis of a confirmed prior
negative test for HIV within the 12 months preceding
diagnosis, (in which confirmation of the test result was
provided by either the doctor or the laboratory), 31
people (all males) would be classified as incident cases.
Of these 31 confirmed incident cases, 28 (90 per cent)
reported male-to-male sexual contact.  In comparison
there were 34 confirmed incident HIV cases diagnosed
in 2000, 18 in 1999, 23 in 1998 and 41 in 1997.
HIV TESTING IN VICTORIA
Laboratories who undertake HIV testing in Victoria
provide a range of de-identified information about the
population undergoing HIV testing.  This enables us to
assess whether any observed increases in HIV
diagnoses are likely to be related to an increase in
testing, or whether the increase is due to some other
reason.  There has been no significant increase in the
total number of tests performed annually in Victoria
since 1995 (Table 3).
DISCUSSION
The recent rise in HIV diagnoses in Victoria has
occurred against a backdrop of increasing rates of other
sexually transmitted infections (STI), in particular
gonorrhoea.1 Similar trends have also been observed in
several other countries including the United Kingdom,
the Netherlands, and several states in North
America.2,3,4 Data from San Francisco suggest that rates
of new infections may also be starting to increase.9
Rises in the number of STI infections are of concern
because not only may they reflect an increase in high-
risk sexual behaviour, but they may also facilitate the
transmission of HIV.5 Surveys of self-reported sexual
behaviour among the gay community, both here and
overseas, also give credence to the likelihood that the
proportion of MSM who engage in unprotected anal
intercourse, with partners of unknown or opposite
serostatus, is increasing.6,7,8
The increase in new HIV diagnoses first observed in
2000 has continued throughout 2001, and may indicate
that this is the beginning of an upward trend. During
this two year period men who have sex with men have
recorded an 88 per cent increase in new diagnoses of
HIV and a 77 percent increase has been observed in
heterosexual women.  Persons who inject drugs,
particularly those from Indochina, continue to record
unacceptably high numbers of new diagnoses. 
A number of projects have been, or are currently being,
developed to identify the reasons behind the increase in
HIV infection in particular sub-groups in Victoria.
Table 3: HIV Testing by Sex and Year of Test, Victoria, 1993–2001
1993 1995 1997 1999 2001*
Males 31,089 56,564 61,672 51,311 53,845
Females 29,517 48,349 58,516 53,642 57,008
Unavailable 1,382 14,779 1,616 17,894 971
Total 61,988 119,692 121,804 122,847 111,824
* Does not include data from one laboratory who reported a total of 13,185 tests in 1999
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These include:
• a case-control study of transmission risks among gay
men;
• a pilot record linkage study to identify the extent of
the inter-relationship between MSM with gonorrhoea
and MSM with HIV;
• a study investigating risk factors for HIV among
persons from Indochina who inject drugs; and
• a project to better identify which heterosexual women
are at risk of HIV and where and how they are
becoming infected. 
The Victorian Infectious Diseases Reference Laboratory has
recently undertaken pilot testing of a new technique, the
“detuned” Elisa, which enables incident HIV infections to
be identified serologically.  The information derived from
this pilot study will be used to validate current
epidemiological methods for identifying incident, or newly
acquired, cases and will add to our understanding of who
is currently becoming infected with HIV.  
Improving our ability to identify incident cases would
enable changing trends in transmission to be identified
more quickly so that prompt public health action can be
taken to limit any outbreak among particular groups.
The 56 percent increase in HIV diagnoses between 1999
and 2001 is unacceptable.  These figures may indicate a
widespread complacency in the community about the
risks of HIV infection and highlight the urgent need for
current prevention efforts to be augmented by new
strategies to reach those at risk of HIV.
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Recent Infection with HIV in Victoria 1999–2000
Determined by “Detuned” EIA
Alan Breschkin, Adam Enriquez and Mike Catton. Victorian Infectious Diseases Reference Laboratory
alan.breschkin@mh.org.au
The recent rise in the number of newly diagnosed cases of HIV infection in Victoria is a concern.  We used a
“detuned” HIV antibody test to determine the number of recent infections among newly diagnosed cases in 1999
and 2000.  Over this two year period 30 per cent (1999) and 38 per cent (2000) of HIV diagnoses occurred within
approximately 170 days of infection.
INTRODUCTION
There were 197 newly diagnosed cases of HIV infection
in Victoria in 2000, a 41 per cent increase compared to
1999.  These cases were all confirmed positive by Western
blot testing at the Victorian Infectious Diseases Reference
Laboratory, which serves as the state HIV reference
laboratory.  However, a new diagnosis of HIV does not
necessarily indicate that the infection was recently
acquired. 
Previously, recent HIV infection could only be recognised
based on a patient’s history of a recent negative or
indeterminate antibody test, or clinical recognition of HIV
seroconversion illness.  In 1998, Jansson et al1 at the
United States’ Centers for Disease Control and Prevention
(CDC) reported a method that could identify recently
acquired cases due to the low level and avidity of HIV
antibody present in the early stage of infection.  At the
time of diagnosis, if the antibody level and avidity are
low, the infection is likely to have occurred recently.  The
assay developed by Jansson et al1 has become known as
the less sensitive or “detuned” enzyme immunoassay
(EIA) method.  Patients who are HIV antibody positive on
a current generation, high sensitivity assay, but negative
on a low sensitivity (or “detuned”) test are presumed to
be recently infected.  Patients who are antibody positive
on both methods are interpreted as having long-standing
infection.
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The less sensitive assay used by Jansson et al1 was the
Abbott Diagnostics HIV-1 lysate EIA (3A11).  The authors
estimated that the mean time interval for seroconversion
on the Abbott 3A11 EIA was 129 + 20 days from time of
infection.  The use of the 3A11-detuned assay to detect
early cases of HIV infection has been trialed in Australia.2
However, Abbott subsequently discontinued production
of this assay.  CDC has validated an alternative “detuned”
assay marketed by Organon Teknika.  The seroconversion
window period with the detuned Organon EIA has been
estimated to be 170 days. The somewhat longer “detuned”
period for the Organon assay is advantageous for public
health purposes, as an incident infection is conventionally
defined to be within 12 months of diagnosis.  We have
used the detuned Organon Teknika assay to test the newly
diagnosed cases of HIV infection from 1999 and 2000 in
Victoria.
METHODS
All cases of HIV infection newly diagnosed in Victoria
in 1999 and 2000 were originally tested by Abbott
Diagnostics HIV-1/HIV-2 gO EIA and confirmed
antibody positive by the Genelab Diagnostics HIV 2.2
Western blot assay.  Retrospective “detuned” testing
was performed using the Organon Teknika Vironostika
HIV EIA (Code 59606), modified according to the CDC
less sensitive protocol.  The modifications were as
follows:
• Very high specimen dilution (1:20,000 final)
• Reduced sample incubation time (30 min at 37oC)
The CDC assay calibrator, low positive control, and
high positive control were kindly supplied by Mr Philip
Cunningham (Centre for Immunology, St Vincent’s
Hospital, Sydney) and were included in triplicate in
each assay run, along with the kit negative control.
Each specimen was tested only once and not repeated
in triplicate, as recommended in the CDC protocol, due
to the limited availability of the calibration reagent.
The optical density (OD) for each control or specimen
well was read at 405nm.  The mean OD of the negative
controls was subtracted from the specimen and
calibrator OD’s, and these values were used to calculate
the standardized OD (SOD) for each specimen
(SOD=specimen OD/calibrator OD).  Specimen SOD’s
less than 1.00 were non-reactive in the less sensitive
assay and considered to indicate recent seroconversion
(within 170 days).
RESULTS
VALIDATION STUDIES
A small study was initially undertaken to validate 
our performance of the Vironostika less sensitive
(“detuned”) assay. Four specimens from patients known
to have long-standing HIV infection and seven
specimens from patients known to have seroconverted
within three months were tested.  The SOD’s for all of
the established infections were greater than 2.0 (range
5.25–7.40) and SOD’s for recent seroconverters were well
below 1.0 (range 0.00–0.62).
Serial serum samples from one patient who had a
history of seroconversion were tested to compare
estimates of the window period for the assay (Table 1).
The patient was first tested EIA reactive, Western blot
indeterminate group IV by our laboratory on a specimen
taken 18 October 2000.  A follow up bleed from 9
November 2000 was confirmed Western blot positive,
consistent with full seroconversion to HIV.  The detuned
SOD on this specimen was 0.094, clearly indicative of
recent infection. The SOD progressively increased on
two follow-up bleeds but remained well below 1.00 at
120 days post diagnosis.  At 280 days follow-up the SOD
was 1.089, the point at which the detuned assay was
borderline positive.  For this individual, the detuned
window period was significantly longer than the 170
day estimate based on the CDC trial.
NEW HIV DIAGNOSES 1999 & 2000
Having established that the detuned Vironostika EIA
was discriminating recently acquired from established
HIV infection, our aim was to test as many of the newly
diagnosed cases from 1999 and 2000 as possible.
Sera remaining from almost all cases of HIV diagnosed
in 1999 and 2000 were tested (Table 2).  Of the 1999
cases, 42 (30.4 per cent) were non-reactive (SOD<1.00)
in the detuned EIA; by comparison 73 (38.0 per cent) of
the 2000 cases were non-reactive.  According to the
CDC protocol a non-reactive result defines a case of
early (i.e. within 170 days) HIV infection.  The recently
acquired infections occurred predominantly in men
Table 1: Correlation of “Detuned” EIA* Results With Days Post
Serological Diagnosis of HIV in One Patient
Bleed Date Days Post HIV SOD+ by 
Diagnosis by “Detuned” 
Western blot EIA*
9.11.00 0 0.094
10.1.01 61 0.224
13.3.01 120 0.439
20.08.01 280 1.089
+ standardised optical density
* enzyme immunoassay
Table 2: “Detuned” Antibody Testing of Newly Diagnosed HIV Cases
Year of Number of Number Tested Number (%) Number (%) Number (%)
Diagnosis New Cases by Detuned EIA Classified Classified Classified
Diagnosed Recent Intermediate Past
in Victoria Infection Infection Infection
(SOD<1.0) (1.0<SOD<2.0) (SOD>2.0)
1999 140 138 42 (30.4) 24 (17.4) 72 (52.2)
2000 197 192 73 (38.0) 24 (12.5) 95 (49.5)
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who had sex with men—69 per cent (1999) and 78 per
cent (2000).  In 2000 seven cases of early infection
occurred in heterosexual intravenous drug users.
An additional 24 cases each in 1999 and 2000 had SOD’s
in the range between 1.0–2.0.  The CDC protocol
recommends that such specimens be re-tested in
triplicate prior to interpreting early infection status.  In
our study this was not done due to limited availability
of assay reagents.
DISCUSSION
The Vironostika “detuned” EIA allowed us to estimate
the frequency of infection for almost all of the newly
diagnosed HIV cases in Victoria for 1999 and 2000. One
advantage of the “detuned” methodology is that it
allows the detection of recent infection in a single blood
specimen, without reliance on the availability of results
from previous HIV antibody testing or recognition of a
seroconversion illness.  Using these latter surveillance
methods, 30 per cent of cases in 1999 and 31 per cent  in
2000 were determined to have acquired HIV infection
within 12 months of diagnosis3. Our estimates of early
HIV infection by “detuned” testing for 1999 (30.4 per
cent) and 2000 (38.0 per cent) were similar to those
obtained from surveillance. However, the surveillance
estimates refer to infection acquired within 12 months
of diagnosis, whereas the period recognised by the
“detuned” assay is only 170 days, according to current
CDC data.  A collaborative study between VIDRL and
the Macfarlane Burnet Institute for Medical Research
and Public Health is planned to further evaluate the
surveillance and “detuned” data on recently acquired
infection. 
The period defining recent infection may be revised as
additional results are obtained with the Vironostika
assay.  For example, the period was approximately 280
days for a series of specimens we tested from a patient
with a well-characterised history of acquisition of HIV
infection. We were unable to test specimens in triplicate
due to limited availability of the assay calibrator. This
may slightly diminish the accuracy of our estimates of
recently acquired infection.  However, we believe the
comparison of 1999 and 2000, which was the main
objective of our study, is valid. 
To bring the “detuned” methodology closer into line
with the conventional definition of incident HIV
infection, it may be useful to include cases for which the
detuned result is in the 1.0–2.0 range, in addition to
those which are non-reactive.  From our results, 47.8 per
cent of cases in 1999 and 50.5 per cent in 2000 had a
result of less than 2.0 and would be classified as recent
infections if this wider definition were employed.
Extensive testing would be required to establish the
validity of this proposal.
Victoria experienced a disturbing rise in the number of
newly diagnosed cases of HIV infection in 2000. From
1999 to 2000, newly diagnosed HIV cases went from 140
to 197, an increase of 41 per cent. Our “detuned” EIA
results indicate that the cases of recent infection
increased more sharply from 42 to 73, a rise of 73 per
cent over this period.  
It is hoped that these results, and further comparison of
cases of recently acquired infections identified by the
“detuned” assay and the surveillance methods, will
contribute to a better understanding of current HIV
transmission patterns and aid in the design of effective
HIV prevention efforts.
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Infectious Diseases News
EMERGENCE OF INFLUENZA B/HONG
KONG/330/2001-LIKE STRAINS
Dr A Hampson, World Health Organisation Collaborating
Centre for Reference and Research on Influenza 
The evolution of influenza B viruses differs from that of
influenza A. For influenza A there is generally a
progression along a single genetic lineage with new
variants replacing their predecessors. Multiple lineages
seldom co-exist for more than a short period of time.
For influenza B, however, it is not uncommon for more
than a single genetic lineage of virus to co-exist in the
population for an extended period and these may be
quite distinct antigenically.
Currently two genetically and antigenically disting-
uishable lineages of influenza B viruses are co-existing in
the human population. There is genetic evidence that
these two groups began to diverge around 1969.
However, it was not until the late 1980s when significant
antigenic differences were recognized and the two
lineages were then characterised according to the
reference strains at that time as B/Victoria/2/87-like or
B/Yamagata/16/88-like.  B/Yamagata lineage viruses
became the predominant influenza B viruses and from
1991 B/Victoria-like strains were observed only in Asia
where their levels have fluctuated from year to year. The
two lineages of influenza B have continued to evolve
independently since that time, however, the genetic and
corresponding antigenic changes in influenza B viruses
occur at a slower rate than for the influenza A viruses,
particularly A (H3N2) strains.
In May–June 2001 a number of B/Victoria-lineage
viruses were observed in Hawaii, their first occurrence
outside Asia in a decade.  At that time there was no
evidence of spread beyond Hawaii, however, a single
23Victorian Infectious Diseases Bulletin Volume 5  Issue 2  June  2002
isolate was found in Canada in association with
overseas travel.  At the time of the WHO and Australian
influenza vaccine formulation recommendations in
September and October 2001 there had been no further
spread. B/Sichuan/379/99-like strains (B/Yamagata-
lineage) were the predominant influenza B viruses;
therefore, a B/Sichuan-like strain was incorporated into
vaccine formulations for the 2002 Southern winter.
Due to the lack of recent experience with virus strains of
the B/Victoria lineage there is reduced background
immunity to B/Hong Kong-like viruses in populations
outside Asia and this is most pronounced in children. In
addition, in these populations antibody responses to
B/Hong Kong-like strains are of reduced frequency and
magnitude in comparison to the vaccine strain when
B/Sichuan-containing vaccines are administered.
During the 2001–2002 Northern Hemisphere winter
some further spread of B/Victoria lineage viruses was
observed in Europe, North America and Africa.
Although B/Sichuan-like strains were still more
numerous overall it was recommended by WHO in
February 2002 that a recent B/Victoria lineage virus (a
B/Hong Kong/330/2001-like strain) should be
included in the vaccine for the 2002–3 Northern
Hemisphere winter.  
It should be noted that the option of including two 
B strains in influenza vaccines, which may be considered
in the current epidemiological situation, gives rise to 
a number of concerns. These include the possibility of
increased lead-time for vaccine production and potential
for reduced vaccine availability plus unresolved
questions regarding the possibility of antigenic comp-
etition between the two related components. Vaccine
trials conducted previously with a 1997 representative of
the B/Victoria lineage suggested that viruses of this type
might induce better responses to the B/Sichuan lineage
than the converse situation, however this remains to be
confirmed.
Currently both influenza B/Sichuan and B/Hong
Kong-like viruses are circulating in Australia and have
been seen in approximately equal numbers, however
influenza A (H3N2) A/Moscow-like strains have been
predominant for the year to date. Reports from Canada,
where widespread activity due to B/Hong Kong-like
strains occurred during the 2001–2 season indicate that
the virus has mainly affected children, as might be
expected, and that few cases were seen in vaccinated
individuals who received the current vaccine containing
a B/Sichuan-like strain.
The current Australian influenza vaccine represents a
good match for the majority of circulating viruses,
particularly the influenza A strains which are most
commonly the cause of serious morbidity and mortality
in the key target groups for whom vaccination is
recommended. It has been reported that even when a
there is a significant antigenic difference between
circulating strains and a vaccine component that
vaccination may still provide a reduction in the severe
outcomes of infection. It remains important, therefore,
to continue to offer vaccination according to the
NH&MRC guidelines.
A NEW INITIATIVE IN THE CONTROL OF
NOSOCOMIAL INFECTIONS IN VICTORIA
The Victorian Nosocomial Infection Surveillance
Coordinating Centre commenced operation in April
2002. It is co-located with the Victorian Infectious
Diseases Reference Laboratory. The Director of the
Coordinating Centre is Dr Mike Richards, Mr Phil
Russo is Deputy Director, and Dr Ann Bull is
Epidemiologist. By June, the full compliment of staff
will include an Information Technology Officer,
Infection Control Practitioners, Educational
Development Officer and Secretary. An Infectious
Diseases Physician will join the Centre in August. 
The Coordinating Centre will establish and support the
Victorian Nosocomial Infection Surveillance System
(VICNISS). VICNISS will play a critical role in reducing
hospital-acquired infections and associated morbidity
and mortality. The ultimate goal of VICNISS is
improving health. 
The Coordinating Centre will receive data and report on
public hospital infection rates for hospitals with more
than 100 beds. This will provide reliable and meaningful
information about Victorian hospital infection rates. The
Centre will feed benchmarked information back to
participating institutions both directly and through
broad publication. Phase one will commence in 10
tertiary hospitals in 2002 and a system for smaller
hospitals will be developed and piloted in 2004.
Further information can be accessed at http://
infectioncontrol.health.vic.gov.au/vicniss.htm.
MURRAY VALLEY ENCEPHALITIS WARNING
FOR NORTHERN AUSTRALIA
The Department of Health & Community Services in
the Northern Territory issued a Murray Valley
encephalitis (MVE) warning for the Top End of the
Northern Territory on 16 May 2002. The warning
followed the seroconversion of sentinel chickens in and
around the Darwin area.
The high-risk period for MVE in Northern Australia
extends until the end of June. Given tourist numbers
increase markedly at this time, travellers are urged to
take precautions to avoid mosquito bites and to take the
appropriate personal protective measures. Clinicians
should consider MVE and Kunjin virus encephalitis in
persons with viral encephalitis who have a history of
travel to endemic areas.
SURVEILLANCE OF INVASIVE GROUP A
STREPTOCOCCAL DISEASE
Invasive group A streptococcal disease (IGAS) is a
serious bacterial infection that has a case fatality rate
approaching 30 per cent.  The incidence and severity of
this disease is increasing worldwide, and possibly
Australia.  The role that this disease plays in the overall
burden of infectious disease in Australia is unknown.
In response to the need for both clinical and risk factor
information, the Department of Human Services (DHS)
and the Department of Paediatrics, University of
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INTRODUCTION
Public health surveillance systems are critical to the
protection of the health and safety of communities and
their effectiveness is dependent on accurate and timely
data from several sources. However, there is an increasing
emphasis on the promotion of the right to privacy and an
individual’s ability to control their personal information.
While the protection of privacy is critical to maintaining
community confidence in public health activities, these
developments have lead to increased tension between the
protection of an individual’s privacy and the protection of
health and safety.1–3
This has particular relevance for the rapid growth in
information technology in all areas of health. The
increasing ability of governments and private
organisations to collect large amounts of personal
information and from multiple data sources allows the
creation of comprehensive health information histories
on individuals and their communities.
Here, we review new privacy legislation in Victoria and
at the national level, outline the key aspects of the
legislation, and discuss the implications for surveillance
of notifiable infectious diseases.
STATE LEGISLATION
HEALTH RECORDS ACT 2001
The Health Records Act 2001 (HRA)4 establishes privacy
standards for the handling of health information.
Compliance with the Act is required from 1 July 2002
and applies to all Victorian organisations—profit and
non-profit, public and private sector—and people who
handle health information. Under the Act, health
information that is collected, held or used by
organisations must be handled in accordance with the
Health Privacy Principles in Schedule 1. 
For the purposes of the Act, health information is
defined to include personal (identifying) information
that is collected by an organisation in the course of
Privacy Legislation and Notifiable Diseases in
Victoria
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Melbourne have implemented an active surveillance
system to research the burden of invasive group A
streptococcal (GAS) disease in Victoria.
As part of the surveillance, all laboratories in Victoria
that perform diagnostic microbiology have been asked
to send notifications to DHS of all isolates of GAS from
a normally sterile site (eg blood & CSF).  We have also
requested that laboratories send these isolates to the
Microbiological Diagnostic Unit Public Health Labora-
tory (MDU) for further testing. In addition to invest-
igating each primary case of IGAS in Victoria, we will
be conducting carriage studies in family members and
close contacts of primary cases.
For further information about this study, please contact
Dr Jonathan Carapetis (03) 9345 4977 or Ms Loraine
Kelpie (03) 9345 7081.
OZFOODNET UPDATE
OzFoodNet is an initiative funded by the
Commonwealth Department of Health and Ageing to
enhance surveillance of food borne disease across
Australia. In Victoria, the Communicable Diseases
Section of the Department of Human Services manages
this project.
Case-control studies for Campylobacter and Salmonella
are major components of the OzFoodNet project nation-
wide; these commenced in Victoria in October 2001 and
are now close to completion. Cases and controls have
been interviewed using a standard questionnaire to
investigate risk factors for infection such as foods
consumed, travel and contact with animals.  
OzFoodNet Victoria is currently planning a general
practice survey to be conducted in August/September
2002.  Randomly selected practices across the state will
be requested to complete a survey on the prevalence of
gastrointestinal illness amongst their patients, the
frequency and reasons for collection of faecal specimens
from those with acute gastroenteritis and their treatment
with antibiotics. The survey will be conducted by mail,
and results will be analysed and reported to participating
clinicians.
PHASE II OF THE NATIONAL Q FEVER
MANAGEMENT PLAN COMMENCES
In 2001, the Federal Government offered $10.6 million
dollars to all States and Territories to implement a Q
Fever screening and vaccination program aimed at
reducing the incidence of Q fever in high-risk groups.
The initial focus was abattoir workers. Additional
funds have now been allocated for 2002/2003 to extend
the program to include livestock and dairy farmers.
To ensure the Q fever campaign is successful, training
for regional and rural general practitioners is
underway. Once training has been established, the
Department will hold a series of mass screening and
immunisation clinics. A pilot project for shearers in the
far west of the state has already been a success, with
more than 80 attending a screening session and
returning a week later for immunisation
25Victorian Infectious Diseases Bulletin Volume 5  Issue 2  June  2002
providing a health, disability or aged care service to a
person, or information that relates to a person's health
or disabilities.
INFORMATION PRIVACY ACT 2000
In December 2000, the Victorian Government passed
the Information Privacy Act 2000 (IPA)5 to establish a
legal framework for the responsible collection and
handling of personal information in the Victorian
public sector. The Act came into partial effect on 1
September 2001 and compliance with the principles is a
legal obligation from 1 September 2002. This legislation
will cover the Victorian public sector and will also
apply to organisations providing services funded by
Victorian Government departments. The IPA does not
cover health information. 
For the purposes of the Act, personal information is
defined as information or an opinion (including
information or an opinion forming part of a database),
that is recorded in any form and whether true or not,
about an individual whose identity is apparent, or can
reasonably be ascertained, from the information or
opinion, but does not include information of a kind to
which Schedule 2 (that is, health information) applies.
The Act has particular provisions for the collection and
use of sensitive information which includes: racial or
ethnic origin; political opinions; membership of a
political association; religious beliefs or affiliations;
philosophical beliefs; membership of a professional or
trade association; membership of a trade union; sexual
preferences or practices; and/or criminal record.
COMMONWEALTH LEGISLATION
THE PRIVACY AMENDMENT (PRIVATE SECTOR)
ACT 2000
The Privacy Amendment (Private Sector) Act 2000 (PAA)6
amends the Commonwealth Privacy Act 1988 to
establish minimum privacy standards for the
Australian private sector, including for all private sector
organisations that provide health services and hold
health information (as defined above).7 This legislation
takes precedence over State or Territory legislation,
only to the extent that these laws are inconsistent.
KEY COMPONENTS OF THE HEALTH RECORDS
ACT
The legislative requirements are based on ten to twelve
privacy principles, which are closely related and largely
consistent between the three Acts (Table 1). The key
aspect of each of the principles is the manner in which
health and identifying information is handled either
with or without the person’s consent.
The Victorian Health Services Commissioner has the
ability to issue statutory guidelines under the HRA
relating to some or all of the privacy principles. Currently
there are two such guidelines, respectively covering the
transfer or closure of a health service and the collection
and use of identifying health information in research.8,9
The Department of Human Services has developed
comprehensive guidelines, which assist in interpreting
and applying the principles to the management of
personal and health information. These guidelines apply
to all DHS services, employees and funded agencies, and
can be accessed on the Department’s website at
http://www.dhs.vic.gov.au/privacy. Non-DHS service
providers may also find the information relevant.
PRIVACY LAWS AND NOTIFIABLE INFECTIOUS
DISEASES
The purpose of the collection of notifiable diseases
information is to monitor and control infectious
diseases in the community and to protect public health
and safety. 
The privacy laws are complementary to existing laws
which override privacy law to the extent that they 
apply. Privacy laws do not negate the obligations
imposed on doctors, laboratories and persons to notify 
a gazetted infectious disease by the Health Act 1958
and Health (Infectious Diseases) Regulations 2001. Notifiers
are required by law to provide specific information,
which includes patient identifiers and demographics,
occupation (or school or child-care attended), indig-
enous status, risk factors, suspected modes of trans-
mission, onset dates and mortality indicators, other
relevant comments and notifier identification. 
Similarly, the Health Act 1958 specifies that “…persons
at risk of contracting or being infected with an
infectious diseases must take all reasonable precautions
to avoid contracting or being infected with the
disease…and must ascertain whether he or she is
infected; and what precautions should be taken to
prevent others being infected;…and must take
necessary measures to ensure that others are not
knowingly placed at risk of becoming infected.”10
Doctors and laboratories do not need to obtain consent
from patients to provide notification information,
however they have an obligation under the HRA to
Table 1: Privacy Principles in Victorian and Commonwealth Privacy
Legislation
Principle Health Information Privacy
Records Privacy Amendment
Act Act Act
Collection √ √ √
Use and Disclosure √ √ √
Quality √ √ √
Security √ √ √
Retention and Disposal √ √ NE
Openness √ √ √
Access and Correction √ √ √
Unique Identifiers √ √ √
Anonymity √ √ √
Transborder Data Flows √ √ √
Sensitive Information NE √ √
Transfer or Closure of a 
Health Service Provider √ NE NE
NE – No equivalent
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BACKGROUND
Although there are many serogroups of meningococci,
serogroups B and C cause most disease in Australia,
with an additional handful due to serogroups W125
and Y, and occasional single cases due to serogroups
29E, X and Z.1 Within the serogroups there are
important differences,2,3 and public health officials and
microbiologists use these to track new strains and
identify potential outbreaks.4,5
In most developed countries, serogroup B causes about
twice as much meningococcal disease as serogroup C,6–8
but in recent years there has been more serogroup C
than serogroup B in Victoria (Figure 1).9 
There is no vaccine to protect from serogroup B disease
in Australia, and despite considerable research, remains
only a distant prospect. 
Following a similar rise in serogroup C cases in the
United Kingdom and the Republic of Ireland, mening-
ococcal serogroup C conjugate (MCC) vaccine was
introduced into the routine immunisation schedule.10
Since being licensed for use in Australia in February
2002, the demand for the new conjugate vaccine 
has been proportionately higher in Victoria than in 
other states. The Public Health Immunisation and
Communicable Diseases Units have answered about 25
calls a day, and distributed large amounts of information
about the vaccine. Of the vaccine distributed so far in
Vaccination Against Serogroup C Meningococcal
Disease
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inform patients that their information is being provided
to the Department. Similarly health information can be
collected without consent if there is imminent and
serious threat to an individual or public health and
safety; these provisions may apply during invest-
igations of outbreaks of infectious diseases. It is,
however, accepted practice that the Department seeks
the consent of both the diagnosing doctor and affected
individual when investigating notified cases and
outbreaks, and the success of these investigations is
dependent on a professional and trusting relationship
between parties. 
The Department of Human Services has recently
reviewed all details requested on the principal
notification form, and supplementary forms, to ensure
that information collected complies with state and
federal legislation. Similarly the need to demonstrate
due process in establishing compliance with the privacy
principles has been addressed in Departmental
protocols for the response to, and management of,
notifications. The Communicable Diseases Section has
produced fact sheets to assist providers and their
patients in understanding the notification process and
the maintenance of the privacy of all information
collected. These are available at http://www.dhs.
vic.gov.au/phd/.
CONCLUSION
Consideration of the rights of the individual versus the
public good has become increasingly important in
public health, heightened by the emergence of diseases
such HIV/AIDS and hepatitis C and the development
of both national and state legislation to protect the
privacy of individuals. While there will always be
difficulties in reconciling competing interests, the
success of disease surveillance and control programs is
highly dependent on health service providers and
public health units taking due care to protect an
individual’s privacy. The new privacy laws demand
that providers are aware of their responsibilities, and
take appropriate measures to ensure their management
of personal and health information is in concordance
with the privacy principles. To maintain public support
for health surveillance, health care professionals should
ensure the community and their clients are aware of the
rationale for health data collections and the
contribution they make to public health and safety.
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Australia, Victorian health care providers have used 53
per cent, with the other states and territories in Australia
combined having provided 47 per cent.
However, as there are now two types of vaccines 
that protect against meningococcal serogroup C, poly-
saccharide and conjugated vaccines which are different in
several significant ways, it is important that the differences
between them are clearly understood by immunisation
providers, public health staff giving advice, and the public
alike. 
MENINGOCOCCAL POLYVALENT
POLYSACCHARIDE VACCINE
The polysaccharide vaccine covers several groups (A, C,
W135,& Y), and has been available for nearly fifty years.11
It has been successfully used in the past to stop outbreaks
of meningococcal disease, including in Victoria.12 There
are however several disadvantages of this vaccine:11
• It produces a diminished response in young children
and for that reason is not licensed for use in children
under the age of two years; 
• It does not provide long-term protection. At best
immunity lasts for five years, and at worst this might
be as little as one year, particularly in children; and
• Response to this vaccine is diminished after the
second or third dose. Hyporesponsiveness is a real
concern in vaccines being used for public health
protection. 
These vaccines provide protection from several
serogroups, but as there has been no serogroup A disease
in Australia since the early 1990s13 there is no need to
vaccinate the population. However, it is a useful vaccine
for travellers to places such as Africa and Asia, where
serogroup A strains are the cause of regular outbreaks,14
and pilgrims to the Hajj where serogroup W135 strains
have recently been a problem.15 The two polysaccharide
vaccines are called Mencevax ACWY (Glaxo SmithKline)
and Menomune (CSL/Pasteur Merieux).
MENINGOCOCCAL SEROGROUP C CONJUGATE
VACCINE
The newly available conjugate vaccine overcomes the
main problems with the polysaccharide vaccine.16,17
• It can be given to all age groups including babies over
six weeks of age.
• At this point in time research provides evidence that
the vaccine will provide long lasting immunity (at
least 15 years).
• Either conjugate or polysaccharide vaccine may be
used as a booster. 
The currently available MCC vaccine is called
Meningitec (Wyeth). Meningitec vaccine is an
inactivated vaccine so it can be administered in a
separate syringe, at a separate site on the same day as
other vaccines or at any time before or after other
vaccines. Two other MCC vaccines are likely to be
licensed in Australia in the near future, called
Menjugate (Chiron/CSL) and NeisVac-C (Baxter).
There are only minor technical differences between
these vaccines, and they are equally effective.18
Meningitec and Menjugate are conjugated to a
diphtheria protein and NeisVac-C to a tetanus protein,
both of which are commonly used in other conjugated
vaccines.  
MCC vaccine should be delayed in people who have a
high fever on the day of the injection or who are
pregnant. Administration technique may need to be
varied in people who have severe latex sensitivity
(because the stopper is made of rubber) and in
thrombocytopenia or coagulation disorder (for whom
intramuscular injection may be contraindicated). MCC
vaccine is contraindicated in people who have
previously had a severe reaction to MCC, diphtheria or
tetanus vaccines.
There are no beef-derived components in the finished
MCC vaccine, although casein (a milk product) is used
during the manufacturing process for Meningitec and
NeisVac-C. The casein is from BSE-free countries,
including Australia. MCC vaccines are also free from
egg and wheat products, nuts, food colouring,
penicillin, aspirin, or any milk products of any kind, so
people with allergies to these items may safely be given
this vaccine. 
MCC vaccines are not live vaccines. They will not cause
meningitis or septicaemia as a side effect. As with other
vaccines, the risk of anaphylaxis is very rare. A few side
effects have been noted with MCC vaccine, most of
them minor. The most common include inflammation at
the injection site, irritability in young children,
headache in about 10 per cent of older individuals, and
sometimes fever over the next few days. The consensus
is that the side effects are fewer and milder than after
the DTPa vaccine.19 There does not seem to be an
increase in side effects when this vaccine is given at the
same time as others. 
The conjugated vaccine can be given at the same time as
other routine vaccines including DTPa, Hib, MMR, Td,
polio, varicella, pneumococcal and influenza. It should
be given separately and not mixed with any of these in
the syringe. There are no published data on co-
administration with hepatitis B, but it is not expected
that there would be an adverse interaction. Similarly,
Figure 1: Notifications of Invasive Meningococcal Disease Due to
Serogroups B and C, Victoria, 1990–2001
0
10
20
30
40
50
60
70
80
Serogroup C
Serogroup B
200120001999199819971996199519941993199219911990
No
tif
ic
at
io
ns
28 Victorian Infectious Diseases Bulletin Volume 5  Issue 2  June  2002
Immunisation Update
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Data cited in this report are based on the Australian Childhood Immunisation Register (ACIR) Coverage Report.
The ACIR report measured immunisation coverage at 31 March 2002 for children aged 12–<15 months and 24–<27
months at 31 December 2001. Only vaccines administered before 12 months of age were included in the coverage
calculation for the former age group, and only those vaccines administered before 24 months of age were included
in the coverage calculation for the latter age group.
there is no published information about administration
with or soon after BCG vaccination, although it is
known to have been not problematic when given within
a month. 
If people have been given meningococcal poly-
saccharide vaccine, for maximum immune response
preferably six months should elapse before giving the
conjugate vaccine,20 unless there is an urgent need to
provide protection in which case it may safely be
administered after a gap of two weeks. Similarly, at least
two weeks should be left after giving the conjugate
vaccine prior to administration of multivalent
polysaccharide vaccine. 
SUMMARY
Remember that there are no vaccines for serogroup B
meningococcal disease in Australia.
Think of meningococcal polysaccharide vaccines as
travel vaccines, which primarily protect from sero-
groups A and W135 abroad. Think of MCC vaccine as
long-term protection from serogroup C disease for all
age groups. MCC vaccines can be given at the same time
as other vaccines. There are very few contraindications
to—or side effects from—MCC vaccines.
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The following table (Table 1) groups immunisation
coverage by Local Government Area for the two birth
cohorts. For a copy of the ACIR report listing
immunisation coverage against individual vaccines for
each local government area, contact Michele Sands
(michele.sands@dhs.vic.gov.au).
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Table 1: Childhood Immunisation Coverage, by Local Government Area (LGA), Victoria, March 2002.
% Fully Total LGAs 
Age Group Immunised Local Government Area (LGA) (% LGAs)  
12–<15 95%+ Ararat (RC), Buloke (S), Campaspe (S), Corangamite (S), Delatite (S), Gannawarra (S), Hindmarsh (S), 16 (21%)
months Loddon (S), Moorabool (S), Moyne (S), Northern Grampians (S), Swan Hill (RC), Wangaratta (RC), 
Warrnambool (C), West Wimmera (S), Yarriambiack (S)
90–94% Alpine (S), Ballarat (C), Baw Baw (S), Bayside (C), Boroondara (C), Brimbank (C), Colac-Otway (S), Darebin (C), 36 (46%)
Glen Eira (C), Glenelg (S), Golden Plains (S), Greater Bendigo (C), Greater Geelong (C), Greater Shepparton (C), 
Hobosons Bay (C), Horsham (RC), Indigo (S), Kingston (C), Knox (C), LaTrobe (C), Macedon Ranges (S), 
Maribyrnong (C), Melton (S), Mildura (RC), Mitchell (S), Moira (S), Moonee Valley (C), Moreland (C), South
Gippsland (S), Southern Grampians (S), Towong (S), Wellington (S), Whitehorse (C), Whittlesea (C), 
Wodonga (RC), Wyndham (C)
85–89% Banyule (C), Bass Coast (S), Cardinia (S), Casey (C), East Gippsland (S), Frankston (C), Greater Dandenong (C), 22 (28%)
Hepburn (S), Hume (C), Manningham (C), Maroondah (C), Melbourne (C), Monash (C), Mornington Peninsula (S), 
Murrindindi (S), Nillumbik (S), Port Phillip (C), Queenscliffe (B), Stonnington (C), Surf Coast (S), Yarra (C), 
Yarra Ranges (S)
80–84% Central Goldfields (S), Mount Alexander (S), Strathbogie (S) 3 (4%)
<80% Pyrenees (S) 1 (1%)
24–<27 95%+ Alpine (S), Ararat (RC), Central Goldfields (S), Corangamite (S), Gannawarra (S), Glenelg (S), Hindmarsh (S), 16 (21%)
months Horsham (RC), Loddon (S), Moira (S), Murrindindi (S), Queenscliffe (B), Southern Grampians (S), Swan Hill (RC), 
West Wimmera (S), Yarriambiack (S)
90–94% Ballarat (C), Buloke (S), Campaspe (S), Cardinia (S), Delatite (S), East Gippsland (S), Glen Eira (C),  25 (32%)
Greater Bendigo (C), Greater Geelong (C), Indigo (S), Knox (C), LaTrobe (C), Maribyrnong (C), Maroondah (C), 
Melton (S), Mitchell (S), Moorabool (S), Northern Grampians (S), South Gippsland (S), Surf Coast (S), Towong (S), 
Warrnambool (C), Whitehorse (C), Whittlesea (C), Wodonga (RC)
85–89% Banyule (C), Bass Coast (S), Baw Baw (S), Bayside (C), Brimbank (C), Casey (C), Colac-Otway (S), Darebin (C), 29 (37%)
Frankston (C), Golden Plains (S), Greater Dandenong (C), Greater Shepparton (C), Hobsons Bay (C), Hume (C), 
Kingston (C), Macedon Ranges (S), Manningham (C), Mildura (RC), Moonee Valley (C), Moreland (C), 
Mornington Peninsula (S), Mount Alexander (S), Moyne (S), Nillumbik (S), Stonnington (C), Wellington (C), 
Wyndham (C), Yarra (C), Yarra Ranges (S)
80–84% Boroondara (C), Monash (C), Port Phillip (C), Pyrenees (S), Strathbogie (S), Wangaratta (RC) 6 (8%)
<80% Hepburn (S), Melbourne (C) 2 (2%)
Surveillance Report
The Department of Human Services receives notifications of infectious diseases from medical practitioners and
laboratories. These notifications prompt investigation and action to control infectious diseases in Victoria. For
some diseases, investigation is initiated on the basis of clinical suspicion in the absence of laboratory
confirmation. Prompt notification of infectious diseases is an integral component of prompt public health action.
Please do not delay. To notify, call 1300 651 160 or fax 1300 651 170.
This section includes a summary of infectious disease notifications received until 31 March 2002. The report has
been produced by the Communicable Diseases Section, Department of Human Services, in cooperation with the
Victorian Infectious Diseases Reference Laboratory and the Macfarlane Burnet Institute for Medical Research and
Public Health. We gratefully acknowledge the contribution of the Microbiological Diagnostic Unit, University of
Melbourne; and  the Melbourne Sexual Health Centre. 
Table 17 includes historical comparisons of selected diseases with 2001 data at both the State and regional level.
Summary data at local government level for the diseases listed are available from Greg Mathews, Communicable
Diseases Section, Department of Human Services (03 9637 4108). There have been no notifications of anthrax,
Australian arboencephalitis, botulism, cholera, diphtheria, Japanese encephalitis, Kunjin virus, plague,
poliomyelitis, rabies, tetanus, viral haemorrhagic fevers or yellow fever. 
For comments or queries related to data for sexually transmissible diseases, contact the Communicable Diseases
Section, Department of Human Services (03 9637 4126). For HIV/AIDS enquiries, contact Cathy Keenan or Dr Nick
Crofts, Epidemiology and Social Research Unit, The Macfarlane Burnet Institute for Medical Research and Public
Health (03 9282 2290). 
Fortnightly surveillance data from the Victorian Infectious Diseases Reference Laboratory are available at
http://www.dhs.vic.gov.au/vidrl/. All data in this report are provisional and subject to revision as further
information becomes available. You can find general information related to the control of infectious diseases (The
Blue Book) on line at http://www.dhs.vic.gov.au/phd/hprot/inf_dis/bluebook/index.htm.
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ENTERIC DISEASES
For the first quarter of 2002 there were 32 outbreaks of
gastrointestinal illness reported to the Department
(Table 1).  Of these, seven outbreaks were considered to
be food borne or probable food borne outbreaks.  Of the
remaining 25, 20 were suspected to have been trans-
mitted by person-to-person contact (Norwalk-Like
Virus (12), Hepatitis A (1), Rotavirus (1), suspect viral
gastroenteritis (6)).
CRYPTOSPORIDIOSIS
An outbreak of gastroenteritis in a caravan park in a
rural area of Victoria was reported on 5 February 2002.
Probable cases were defined as a person who attended
the caravan park between 26–29 January 2002 and had
onset of a gastrointestinal illness consisting of two or
more symptoms of diarrhoea, abdominal pain and
nausea. Cases were confirmed if C. parvum was isolated
from a faecal specimen. 
Eleven confirmed and eight probable cases were
identified amongst a group of 21 persons attending 
the park over the weekend. The suspected source was
the park’s swimming pool where all cases had been
swimming. The two people who were not ill had 
not been swimming. Environmental investigations
suggested there were ongoing problems with ducks
swimming in the pool. Water and duck faecal samples
were negative for C. parvum. The pool was closed until
results of water samples were obtained and the pool
owners undertook superchlorination and other pool
hygiene procedures.
HEPATITIS A
On 9 January 2002, the Communicable Diseases Section
was notified of a case of Hepatitis A in a teacher at a
childcare centre in southern Victoria. Between 9 January
and 11 February, 11 confirmed cases were identified
amongst teachers, siblings and parents of children who
attended the centre, with onsets of illness between 28
December 2001 and 9 February 2002. Control measures
included providing information to families, primary
schools and teachers in the area about the outbreak and
prevention measures, and clean-up procedures at the
centre. 
Recommendations for testing of potentially exposed
persons for Hepatitis A IgM and the receipt of immuno-
globulin were based on the last possible day of exposure,
incubation period of Hepatitis A, and the onset dates of
the confirmed cases. While immunoglobulin was
recommended for the families of six cases, it was not
given as parents refused or because treating doctors had
given them Hepatitis A vaccine instead.
FESTIVAL OUTBREAK
A large outbreak of food poisoning was reported in
Melbourne in late March. Over 272 people sought
medical care and although 15 were admitted to hospital
overnight, symptoms were short-lived. The onset of
gastroenteritis was between one and four hours after
consumption of a meal of rice, lamb and potatoes
served at a New Year Islamic festival. Bacillus cereus and
Staphylococcus aureus were confirmed as the cause of the
outbreak. Inadequate storage and handling of leftover
Table 1: Outbreaks of Gastrointestinal Illness, 1 Jan–31 Mar 2002
Setting Outbreaks Persons Affected Pathogen/Toxin (number of outbreaks)
Restaurant / Reception / 6 93 Norwalk-like Virus (1)
other food premises / specific food Suspect viral (1)
Unknown (4)
Aged / disability /Health Care Institution 13 401 Norwalk-like Virus (8)
Rotavirus (1)
Suspected viral (3)
Unknown (1)
Recreation / holiday / Camp 6 102 Norwalk-like Virus (2)
Cryptosporidium (1)
Suspected viral (3)
Children’s Service / School 2 19 Hepatitis A (1)
Norwalk-like Virus (1)
Family / social gathering 3 35 Salmonella Typhimurium 135 (1)
Unknown (2)
Workplace 1 4 Norwalk-like Virus (1)
Festival 1 272 Staphylococcus aureus enterotoxin & Bacillus cereus (1)
TOTAL 32 926 Norwalk-like Virus (13)
Cryptosporidium (1)
Hepatitis A (1)
Rotavirus (1)
Salmonella Typhimurium 135 (1)
Staphylococcus aureus enterotoxin & Bacillus cereus (1)
Suspect viral (7)
Unknown (7)
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food was thought to be the mechanism by which food
became unsuitable for consumption.
BLOODBORNE VIRUSES
ACUTE HEPATITIS B
Notifications of acute hepatitis B increased in 2000 to
115 cases, an 18 per cent increase from 1999. This
increase was partly due to more complete reporting
from hospital laboratories.
Notifications continued to increase in 2001 with a
marked increase in May and June (Figure 1). A total of
196 cases of acute hepatitis B were notified in 2001, a 58
per cent increase from 2000.
Routine surveillance had identified the outbreak,
which also identified an increase in injecting drug use
(IDU) as a risk factor. In 1997 and 1998, approximately
30 per cent of cases were reported to have a history of
IDU, which increased from 53 per cent in 1999 to 61 per
cent in 2001.To improve the identification of risk factors
for acute hepatitis B infection, enhanced surveillance
was undertaken from 1 July to 31 December. This
process involved contacting cases directly to obtain
illness histories and risk factor information, rather than
from their treating doctor only.
Sixty-three (32 per cent) cases were not symptomatic
and were tested for other reasons. Seventy-three per
cent of cases were born in Australia. Risk factors
identified during both the routine and enhanced
surveillance periods are outlined in table 2. Seventy-
seven cases (40 per cent) were co-infected with another
blood borne virus; 75 with hepatitis C and two with
HIV. Acute hepatitis C infection was also identified in
nine cases. 
Interviews with persons with a history of IDU during
the enhanced surveillance indicates that some are still
sharing needles, syringes and other equipment. Health
care workers are encouraged to promote hepatitis B
vaccination, safe injecting practises and safe sex for all
their clients; especially those considered to be engaging
in unsafe behaviours.
NEWLY ACQUIRED HEPATITIS C
Of the 1400 notifications of hepatitis C in the first
quarter of 2002, 20 (1.4 per cent) were classified as
newly acquired. Of these, 12 (60 per cent) were male
with a median age of 23 years (range: 16–45). For the
eight females, the median age was 26 years (range:
15–40). Injecting drug use was identified as a risk factor
in 16 cases (80 per cent). Seroconversion to HCV
antibodies in the preceding 24 months was the basis of
diagnosis for 16 cases (80 per cent).
VACCINE PREVENTABLE DISEASES
HAEMOPHILUS INFLUENZAE TYPE B
There was one notification of Haemophilus influenzae
type b septicaemia in March. The adult case had been
admitted for elective surgery to remove a pancreatic
cyst and developed fevers and a productive cough the
day of the surgery. Sputum cultures were also positive
for non-typable Haemophilus influenzae. The case was
admitted to intensive care and treated successfully with
intravenous ceftriaxone. 
INVASIVE PNEUMOCOCCAL DISEASE
Between 1 January and 31 March 2002, 65 notifications
of invasive pneumococcal disease were received for 32
males and 33 females. The median age of cases was 33
years (range 0–87 years). There were no notifications
for persons of Aboriginal and/or Torres Strait Islander
origin. Twenty-three cases (35 per cent) were aged less
than five years and 24 cases (37 per cent) were aged
greater than 50 years. There were five deaths (case
fatality rate of 7.6 per cent); one in a child aged five
years and four in adults aged 43, 50, 68 and 84 years. Of
those who died, all were unvaccinated and three were
eligible for the polysaccharide pneumococcal vaccine at
no charge.
Of the notifications for which serotype was known (n =
41, 63 per cent), 100 per cent were serotypes included in
the 23 valent polysaccharide vaccine and 87 per cent
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Figure 1: Acute Hepatitis B Notifications, by Onset Month, Victoria,
1998–2001
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Table 2: Risk Factors For Acute Hepatitis B Infection, Victoria, 2001
Risk factor Jan–June July–Dec Total (Per cent)
Routine Enhanced
IDU 49 50* 94 (48)
Heterosexual contact# 22 19 41 (21)
IDU + heterosexual 12 13 25 (13)
contact
No risk identified 3 9 12 (6)
Non occupational 2 5 7 (3.5)
exposure to blood
Male to male sexual 1 5 6 (3)
contact
Other drug use❖ 2 4 6 (3)
Overseas born 0 2 2 (1)
Household contact# 0 1 1 (0.5)
Iatrogenic 0 1 1 (0.5)
No information available 1 0 1 (0.5)
Total 87 109 196 (100)
* Fist fight/current IDU 1 case
# Contact with a hepatitis B infected person
❖ Bongs, snorting equipment
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were included in the 7 valent conjugate vaccine. Three
cases had documented evidence of receipt of the
polysaccharide vaccine within the previous five years,
and one case (aged 33 years with asplenia) had received
a single dose of the conjugate vaccine. All vaccinated
cases were due to strains contained in both vaccines (23
F, 14 and 9V). 
The polysaccharide pneumococcal vaccine is available
free of charge to all persons aged 65 years and older,
Aboriginal and/or Torres Strait Islanders persons aged
50 years and over and those aged 15 to 49 years with
certain health risks, and for all public hospital
outpatients and inpatients with chronic cardiac
disorders, diabetes and metabolic/renal disorders,
asthma and chronic respiratory disorders and
immunosuppression. The conjugate vaccine is not
recommended for use in adults as the polysaccharide
vaccine provides protection against a broader range of
serotypes.
OTHER NOTIFIABLE DISEASES
LEGIONELLOSIS
Between 8 to 30 April 2002, the Department was
notified of eight cases of Legionella  pneumophila sero-
group 1 in visitors to the centre of Melbourne in the
vicinity of the Swanston Street and Collins Street
junction. Three cases worked in the central CBD, two
visited, as part of their work duties, and the other three
cases were casual visitors. 
Due to the cluster of cases in place and time, an
investigation was commenced. All cooling towers in
the area bounded by Flinders Lane and Bourke Street
between Elizabeth Street to the west and within
approximately 100 metres to the east of Swanston Street
were sampled and disinfected. One tower tested
positive for L pneumophila 1 at high levels while another
grew low levels of a Legionella strain unrelated to the
human cases.
No cases visited or worked in or adjacent to the building
with a tower positive for L pneumophila 1. Despite
obtaining human specimens for culture, Legionella was
not grown from any sputum samples. Without isolates
for subtyping it is difficult to confirm the association
between cases and a positive cooling tower.
MENINGOCOCCAL DISEASE
In the first quarter of 2002 DHS received 37
notifications of invasive meningococcal disease (Table
3). Of these, eight were confirmed as serogroup B,
eleven as serogroup C, and two as W135 (unconnected
to each other). There were a further six cases who were
confirmed by laboratory tests (eg. gram negative
diplococci in the CSF) but for whom serogroup
information is unavailable, and 10 cases with clinically
compatible illnesses for whom laboratory tests were
negative or no appropriate specimens were available. 
Prior to the introduction of PCR as a diagnostic tool, one
third of cases were diagnosed on the basis of a clinically
compatible illness. That we do not know the serogroup
for 10 of the 13 cases under 15 years old, despite
laboratory confirmation for four, may reflect a
reluctance to collect cerebrospinal fluid in children with
meningitis. Two young adult cases—one confirmed as
serogroup C and the other a laboratory confirmed case
—were acquaintances that had attended the same party. 
The geographical distribution is different for
serogroups B and C. Serogroup B cases have been
widely distributed, notified from the Northern
Metropolitan, Barwon South West, Grampians, Hume,
Western and Southern Metropolitan regions, and none
from Loddon-Mallee and Gippsland. Serogroup C
cases have been largely from the Metropolitan area,
with three each from the Northern and Southern
Metropolitan areas, two from Eastern Metropolitan
region, and one from Geelong in Barwon South West. 
LEPROSY
The Department was notified of the first case of leprosy
(Hansen's Disease) since 1999, in an Indian born man
who had been living in Australia and returned to visit
India in 2000. The patient had a history of symptoms as
a child, which resolved without treatment. More
recently he developed areas of hypopigmentation on
his leg, buttock and then on one side of his face. Whilst
in India he was diagnosed with leprosy following
biopsies that were suggestive of borderline tuberculoid
/ borderline lepromatous Hansen's disease. 
The patient was commenced on treatment of
rifampicin, ofloxacin and cynomycin monthly in
addition to dapsone and clofazamine daily for twelve
months. On return to Australia the patient will
continue on rifampicin monthly and dapsone daily for
a further two years to ensure complete resolution.
Follow up of family contacts requires that child
household contacts should receive BCG vaccination.
VECTOR BORNE DISEASES
BARMAH FOREST VIRUS DISEASE
An outbreak of Barmah Forest Virus disease (BFVd) was
identified among residents and visitors to the Gippsland
area in the first five months of 2002.  In total 47 cases of
BFVd were notified to DHS, and 40 were interviewed (85
per cent).  Of the 47 cases, 38 were from the Gippsland
area, 34 within the East Gippsland Shire. Four cases were
linked to Gippsland as visitors and the remaining five
cases had no link to Gippsland and were infected in
other areas. The most common symptoms among those
interviewed were arthralgia, (90 per cent), lethargy (90
per cent) and a maculopapular rash (73 per cent). 
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Table 3: Notifications of Meningococcal Disease, by Age Group and
Serogroup, Victoria, Jan–Mar 2002.
< 5 5–14 15–29 ≥30 Total
years years years years
Serogroup B 1 0 6 1 8
Serogroup C 0 1 8 2 11
Other or unknown 8 3 4 3 18
serogroup 
TOTAL 9 4 18 6 37
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Over the same period of time there were only 21
notifications of Ross River Virus disease (RRVd) in
Victoria, compared to 326 for 2001.  This was the first
time since data was available that BFVd cases
outnumbered RRVd cases.  This outbreak had the
highest number of cases in the first five months of the
year since the outbreak of BFVd and RRVd in the
Loddon Mallee region of Victoria in 1993 in which there
were 53 cases of BFVd and 1109 cases of RRVd.
SEXUALLY TRANSMISSIBLE INFECTIONS
ACQUIRED IMMUNE DEFICIENCY SYNDROME
There were nine cases of AIDS notified during the first
quarter of 2002—six males and three females (Table 4).
Three men (50 per cent) attributed their infection to
heterosexual exposure, of the remainder one man was
from a high prevalence country, one reported injecting
drug use as their only exposure and one attributed his
exposure to male-to-male sexual contact. Two of the cases
in females were attributed to sexual contact and the
remaining female was from a high prevalence country. 
Of the 59 individuals notified with AIDS during the 
12-month period from April 2001 to March 2002 
(49 males, nine females and one transgender
individual), 44 (75 per cent) were notified within three
months of diagnosis, a further two individuals were
notified within one year of diagnosis. In the remaining
11 cases, the delay in notification ranged between two
and nine years.  
There were 1948 people notified with AIDS from 1983
to 31 March 2002—1854 males, 85 females and nine
transgender individuals.  Over 90 per cent of all males
notified have reported male-to-male sexual contact.
Three people, all males, who had been diagnosed with
either HIV or AIDS were notified as having died during
the first quarter of 2002 (Table 5).  Between 01 April
2001 and 31 March 2002, 34 deaths were notified and
since 1983, there have been 1617 deaths recorded.  Of
these 1617 individuals, 1467 (91per cent) had been
previously diagnosed with AIDS whereas 150 had not
been notified as having progressed to AIDS.
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Table 4: Notifications of AIDS in Victoria, Jan–Mar 2002, Apr 2001–Mar 2002 and Cumulative Total since 1983
Exposure Category Jan–Mar 2002 April 2001–Mar 2002 Cumulative Total
Males Females Males Females Males Females Total#
Male homosexual/bisexual 1 – 32 – 1571 – 1576
Male homosexual/bisexual and 0 – 1 – 99 – 103
injecting drug user
Injecting drug user 1 0 1 0 23 12 35
Heterosexual 3 2 8 3 68 51 119
Person from specified country* 1 1 3 3 18 10 28
Haemophilia/related disorder 0 0 0 0 39 1 40
Transfusion recipient 0 0 0 0 8 5 13
Other 0 0 0 1 1 2 3
Unavailable 0 0 4 2 27 4 31
Total 6 3 49 9 1854 85 1948
# Includes persons for whom sex is reported as transgender
* Persons from countries with a high prevalence (>1per cent) of HIV
Table 5: Notifications of Deaths Following HIV/AIDS Diagnosis in Victoria, Jan–Mar 2002, Apr 2001–Mar 2002 and Cumulative Total since 1983
Exposure Category Jan–Mar 2002 April 2001–Mar 2002 Cumulative Total
Males Females Males Females Males Females Total#
Male homosexual/bisexual 2 – 11 – 1215 – 1217
Male homosexual/bisexual and 1 – 2 – 76 – 78
injecting drug user
Injecting drug user 0 0 1 0 15 6 21
Heterosexual 0 0 0 0 31 38 69
Person from specified country* 0 0 0 2 6 5 11
Haemophilia/related disorder 0 0 1 0 29 1 30
Transfusion recipient 0 0 0 0 6 4 10
Other 0 0 0 0 0 0 0
Unavailable 0 0 16 1 32 3 35
Total 3 0 31 3 1395 57 1617
# Includes transgender individuals and individuals for whom gender is not specified
* Persons from countries with a high prevalence (>1per cent) of HIV
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Table 7 Notifications of HIV in Victoria, by Exposure Category, Jan–Mar 2002, Apr 2001–Mar 2002 and Cumulative Total since 1983
Exposure Category Jan–Mar 2002 April 2001–Mar 2002 Cumulative Total
Males Females Males Females Males Females Total*
Male homosexual/bisexual 41 – 143 – 3547 – 3563
Male homosexual/bisexual and 1 – 6 – 207 – 210
injecting drug user
Injecting drug user 1 0 8 2 124 38 165
Heterosexual 10 6 23 14 191 153 344
Person from specified country# 5 3 7 8 76 45 121
Haemophilia/related disorder 0 0 1 0 101 1 102
Transfusion recipient 0 0 0 0 20 15 35
Other 0 0 0 2 4 11 15
Unavailable 0 1 12 1 118 3 143
Total 58 10 200 27 4388 266 4697
* Includes 17 persons for whom sex is reported as transgender and 26 persons for whom sex is not specified
# Persons from countries with a high prevalence (>1per cent) of HIV
Table 6: Notifications of HIV in Victoria, by Age Group, Jan–Mar 2002, Apr 2001–Mar 2002 and Cumulative Total since 1983
Age Group Jan–Mar 2002 April 2001–Mar 2002 Cumulative Total
Males Females Males Females Males Females Total#
0–12 0 0 1 2 30 11 41
13–19 1 0 4 1 81 8 90
20–29 17 1 47 4 1497 105 1617
30–39 22 7 88 14 1606 83 1699
40–49 10 1 29 5 715 31 748
50–59 6 0 17 0 271 16 288
60+ 2 0 0 0 101 1 117
Unavailable 0 1 4 1 87 11 98
Total 58 10 200 27 4388 266 4697
# Includes 17 persons for whom sex is reported as transgender and 26 persons for whom sex is not specified
HUMAN IMMUNODEFICIENCY VIRUS INFECTION
There have been 68 new HIV diagnoses in Victoria
during the first quarter of 2002; 58 males and 10
females, compared with a total of 58 cases notified
during the same quarter in 2001 (Table 6).  The median
age of those notified was 35 years (range: 19 to 68
years), with males being younger on average (34 years
compared with 37 years). The majority (71 per cent) of
males notified during this quarter reported male-to-
male sexual contact (Table 7).  
There were 228 HIV notifications in Victoria received
during the 12 months from April 2001 to March 2002—
200 (88 per cent) males, 27 (12 per cent) females and one
transgender individual. This is a 16 per cent increase on
the 197 notifications reported between 1 April 2000 and
31 March 2001.
Those with newly acquired HIV or incident infection
provide a picture of who is presently affected by the
HIV epidemic.  Such individuals are identified on the
basis of a previous negative HIV test and/or a
seroconversion illness within the 12 months preceding
HIV diagnosis.  There were 24 individuals notified with
incident HIV infection during the first quarter of 2002—
20 males and 4 females.  In the period 1 April 2001 to 31
March 2002, 69 individuals fulfilled the criteria of
incident infection.  These numbers are slightly higher
than the 66 individuals reported with incident HIV
infection during the preceding 12 months.  
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CHLAMYDIA INFECTIONS
The Department received 1184 notifications of
Chlamydia trachomatis (C.trachomatis) in the first quarter
of 2002, representing a 14 percent increase on the
number of notifications from the previous quarter
(n=1038).  It is also an increase of 21 per cent on the
same period last year (n=978).  The age and sex
distribution remains unchanged with the greatest
burden of disease conferred in 20–24 year old age
group (Table 9).  In this same age group, the notification
rate is 549 per 100,000/yr for females and 268 per
100,000/ yr for males.
Table 8: Notifications of HIV in Victoria, by Time Since Last Negative Test or Seroconversion Illness, Jan–Mar 2002 and Apr 2001–Mar 2002.
Time between HIV Diagnosis and Negative Test and/or Jan–Mar 2002 April 2001–Mar 2002
Seroconversion Illness Males Females Total* Males Females Total*
Less than 1 year 20 4 24 66 3 69
1 year to less than 3 years 4 1 5 23 1 25
3 or more years 10 1 12 37 1 38
No previous negative test or seroconversion illness 24 4 27 74 22 96
Total 58 10 68 200 27 228
* Includes one person for whom sex was reported as transgender.
Table 9: Notifications of C. trachomatis in Victoria, by Age Group and Sex, Jan–Mar 2002 and Apr 2001–Mar 2002.
January–March 2002 April 2001–December 2001
Age group Male Female Total Male Female Total
0–4 years 0 0 0 0 1 1
5–9 years 0 0 0 0 0 0
10–14 years 1 3 4 3 8 11
15–19 years 34 172 206 126 592 718
20–24 years 151 260 411 475 928 1403
25–29 years 126 129 255 424 487 911
30–34 years 82 74 156 268 232 500
35–39 years 33 30 63 170 122 292
40–44 years 25 13 38 109 56 165
45–49 years 14 11 25 64 24 88
50–54 years 10 6 16 36 16 52
55–59 years 2 1 3 18 6 24
60–64 years 3 0 3 6 0 6
65–69 years 0 0 0 2 1 3
70–74 years 0 0 0 1 0 1
75–79 years 1 0 1 1 0 1
80–84 1 2 3 1 2 3
Unknown 0 0 0 1 2 3
Total 483 701 1184 1705 2477 4182
Whilst the highest number of notifications were
received from the Southern and Eastern Metropolitan
regions, notification rates were highest in the Western
Metropolitan region and lowest in the Grampians
region.
The most common method of diagnosis of C. trachomatis
infection reported was by nucleic acid testing (Table 10).
The implications of test sensitivity need to be
considered when analysing the trends in notifications of
chlamydia, as an increase in the sensitivity and ease of
testing is likely to lead to an increase in the number of
notifications. 
Table 10: Testing Method Reported by Laboratories for C. trachomatis
Notifications, Victoria, Jan–Mar 2002. 
Testing method Number Percent
Nucleic Acid Testing 1092 92.2
Enzyme Immunoassays 35 3.0
Antibody Fluorescence Testing 33 2.8
Not stated 23 1.9
Culture 1 0.1
Total 1184 100.0
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GONORRHOEA INFECTIONS
Surveillance of gonorrhoea was transferred from 
the Microbiological Diagnostic Unit (MDU) to the
Department from 10 January 2002. As the recording of
notifications differs slightly between the two
organisations there will be minor discrepancies in the
number of notifications reported between the two time
periods.  MDU record notifications based on the
specimen date and the Department records on the date
the notification was received.  
There were 171 cases of gonorrhoea notified during the
first quarter of 2002. This represents a decrease
compared with the 181 cases notified during the first
quarter of 2001. The quarterly count is also lower than
the 204 cases in the corresponding quarter in 2000, and
is consistent with the average number of first quarter
notifications for the years 1998–2002 (n=172). Of the first
quarter notifications, 157 (92 per cent) were for males
and 14 (8 per cent) were for females. The age and sex
distribution is described in Table 11. The median age of
males was 29 years (range: 17–61) and the median age
for females was 26 years (range 21–38 years). 
Table 11: Gonorrhoea Notifications, by Age Group and Sex, Jan–Mar 2002 and Apr 2001–Mar 2002, Victoria.
January–March 2002 April 2001–March 2002
Age group Male Female Total Male Female Total
0–14 years 0 0 0 0 0 0
15–19 years 5 0 5 26 3 29
20–24 years 17 3 20 91 14 105
25–29 years 43 4 47 145 11 156
30–34 years 40 6 46 132 11 143
35–39 years 24 1 25 93 11 104
40–44 years 17 0 17 59 0 59
45–49 years 5 0 5 33 1 34
50–54 years 5 0 5 24 3 27
55–59 years 1 0 1 9 2 11
60–64 years 0 0 0 6 0 6
65–69 years 0 0 0 4 1 5
70 + years 0 0 0 0 0 0
Total 157 14 171 622 57 679
Risk factor information is provided to the Department
by the notifying clinician. This information was avail-
able for 91 per cent (n=155) of notifications. Infection
was most commonly acquired in Victoria from casual
sexual partners (Table 12).
Table 12: Notifications of Gonorrhoea by Gender, Source Partner and Reported Place of Acquisition, Jan–Mar 2002.
Gender Sexual Partner Victoria Interstate Overseas Not stated Total
Male Casual Partner 72 5 10 3 90
Regular Partner 26 0 1 2 29
Sex Worker 3 0 2 0 5
Unknown 7 2 4 20 33
Female Casual Partner 4 0 0 0 4
Client (partner is sex worker) 2 0 0 0 2
Regular Partner 4 0 1 0 5
Unknown 1 0 0 2 3
Total 120 7 18 27 171
In males, the most common site for a positive test was
the urethra and for females the cervix/vagina (Table
13).  Twenty-one per cent of cases (n=36) reported were
diagnosed solely by detection of N. gonorrhoeae by
nucleic acid amplification (such as PCR).
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Testing for antibiotic susceptibility is currently only
possible if N. gonorrhoea is isolated by culture. In the
first quarter of 2002, sensitivity-testing results were
received on 111 of 135 (82 per cent) cases diagnosed by
culture.  Nine people were found to have resistance to
ciprofloxacin.  Table 14 shows the sexual partner and
place of acquisition for these nine cases. 
SYPHILIS
In the first quarter of 2002, one case of infectious
syphilis was reported in a 23-year-old, heterosexual
male.  For the same period last year there were four
cases notified. 
Table 14: Gender, Gender of Partner and Place of Acquisition of Ciprofloxacin and Ceftriaxone Resistant Isolates of N. gonorrhoeae, Victoria, Jan–Mar
2002
Gender Sexual Partner Where acquired Ceftriaxone resistant Ciprofloxacin resistant
(MIC >=0.25) (MIC >0.5 mcg/mL)
Male Female Overseas 0 2
Male Overseas 0 2
Unknown Overseas 0 2
Unknown Unknown 0 1
Female Male Victoria 0 1
Unknown Overseas 0 1
Table 13: Positive N. gonorrhoeae Tests by Sex and Site of Infection,
Victoria Jan–Mar 2002
Site of infection Female Male
Cervix/Vagina 14 0
Pharynx 5 17
Rectal 0 18
Urethral 1 184
Urine 1 30
Other Site 1 1
Not Stated 3 25
Total 25 275
MYCOBACTERIUM REFERENCE LABORATORY
REPORT
Due to the slow growing nature of Mycobacterium spp.
this report is presented with a one period delay to
maintain accuracy. Most specimens (both primary and
referred) and isolates are from Victorian patients. The
majority of non-Victorian specimens originate in the
Northern Territory and the Solomon Islands.
Table 15: Specimens Submitted to the Mycobacterium Reference
Laboratory, Jan–Mar 2002
Primary Specimens
M. tb New Victorian Non M. tb Negatives Total
Isolates M. tb Isolates isolates
January 13 3 26 467 506
February 6 1 10 378 394
March 2 2 12 352 366
Referred Specimens
M. tb New Victorian Non M. tb Negatives Total
Isolates M. tb Isolates isolates
January 28 18 36 64
February 22 11 40 62
March 40 14 30 70
Total 111 49 154 1197 1462
Figure 2: New M. tuberculosis Isolates, by Age Group and Gender,
Victoria, Jan–Mar 2002
0
2
4
6
8
10
Female
Male
90
–9
9
80
–8
9
70
–7
9
60
–6
9
50
–5
9
40
–4
9
30
–3
9
20
–2
9
10
–1
9
0–
9
Nu
m
be
r o
f I
so
la
te
s
Age group (years)
38
• M. kansasii: isolated from pulmonary specimens of
five mainly elderly patients, two males and three
females.  Two patients had multiple isolations and
one had concurrent isolation of M. avium complex.
• M. fortuitum: a rapid growing Mycobacteria sp. which
can cause wound infections, was isolated from leg
ulcers of a 64 year old male and a 10 year old boy.
This organism was also isolated from a shoulder
wound of a dog following a dog bite.
• M. marinum: a referred isolate from a poison arrow
frog.
• M. ulcerans: M. ulcerans PCR was requested for 40
specimens. There were seven positive results from six
patients. Two specimens were from a patient who
had been previously positive.  The PCR results were
confirmed by culture, except in one instance where a
previously positive patient had a negative PCR result
but the organism was isolated in culture.  In addition
M. ulcerans was identified from a referred isolate
from another patient where PCR was not requested.  
• Molecular identifying techniques were used to
identify or confirm identification of 17 isolates,
including one of M. shimodei from two different
patients. This organism is a rare cause of pulmonary
disease and when relying on biochemical tests only it
may be mistaken for M. terrae complex which rarely
causes disease.
• Mycobacterium generic PCR was performed on 23
specimens, including 15 paraffin embedded tissue
biopsies, 3 sputa, 1 bone marrow, 1 lymph node and
1 vitreous humour. M. haemophilum was identified
from a paraffin embedded skin biopsy.
Victorian Infectious Diseases Bulletin Volume 5  Issue 2  June  2002
Table 16: Extra-Pulmonary M tuberculosis Isolates and Resistant Isolates, Jan – Mar 2002
January February March
Pulmonary 10 7 11
Extrapulmonary 11 5 5
Extrapulmonary Site Details Lymph node (x6) Lymph node (x3) Lymph node (x3) 
Pleural fluid (x2) Pleural bx (x1) Pleural fluid (x1)
Wrist (x1)Testicular abscess (x1) CSF (x1)
Rib Abscess (x1)
Bone Asp (x1)
Resistance 2x resistance to Isoniazid
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